Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer
After a median of nearly 4 years of follow-up, the use of radiotherapy combined with chemotherapy in patients with stage III or IVA endometrial carcinoma was not associated with longer relapse-free survival than the use of chemotherapy alone.
Saved in:
| Published in: | The New England journal of medicine Vol. 380; no. 24; pp. 2317 - 2326 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
United States
Massachusetts Medical Society
13.06.2019
|
| Subjects: | |
| ISSN: | 0028-4793, 1533-4406, 1533-4406 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | After a median of nearly 4 years of follow-up, the use of radiotherapy combined with chemotherapy in patients with stage III or IVA endometrial carcinoma was not associated with longer relapse-free survival than the use of chemotherapy alone. |
|---|---|
| AbstractList | BackgroundStage III or IVA endometrial cancer carries a significant risk of systemic and locoregional recurrence.MethodsIn this randomized phase 3 trial, we tested whether 6 months of platinum-based chemotherapy plus radiation therapy (chemoradiotherapy) is associated with longer relapse-free survival (primary end point) than six cycles of combination chemotherapy alone in patients with stage III or IVA endometrial carcinoma. Secondary end points included overall survival, acute and chronic toxic effects, and quality of life.ResultsOf the 813 patients enrolled, 736 were eligible and were included in the analysis of relapse-free survival; of those patients, 707 received the randomly assigned intervention (346 received chemoradiotherapy and 361 received chemotherapy only). The median follow-up period was 47 months. At 60 months, the Kaplan–Meier estimate of the percentage of patients alive and relapse-free was 59% (95% confidence interval [CI], 53 to 65) in the chemoradiotherapy group and 58% (95% CI, 53 to 64) in the chemotherapy-only group (hazard ratio, 0.90; 90% CI, 0.74 to 1.10). Chemoradiotherapy was associated with a lower 5-year incidence of vaginal recurrence (2% vs. 7%; hazard ratio, 0.36; 95% CI, 0.16 to 0.82) and pelvic and paraaortic lymph-node recurrence (11% vs. 20%; hazard ratio, 0.43; 95% CI, 0.28 to 0.66) than chemotherapy alone, but distant recurrence was more common in association with chemoradiotherapy (27% vs. 21%; hazard ratio, 1.36; 95% CI, 1.00 to 1.86). Grade 3, 4, or 5 adverse events were reported in 202 patients (58%) in the chemoradiotherapy group and 227 patients (63%) in the chemotherapy-only group.ConclusionsChemotherapy plus radiation was not associated with longer relapse-free survival than chemotherapy alone in patients with stage III or IVA endometrial carcinoma. (Funded by the National Cancer Institute; ClinicalTrials.gov number, NCT00942357.) Stage III or IVA endometrial cancer carries a significant risk of systemic and locoregional recurrence.BACKGROUNDStage III or IVA endometrial cancer carries a significant risk of systemic and locoregional recurrence.In this randomized phase 3 trial, we tested whether 6 months of platinum-based chemotherapy plus radiation therapy (chemoradiotherapy) is associated with longer relapse-free survival (primary end point) than six cycles of combination chemotherapy alone in patients with stage III or IVA endometrial carcinoma. Secondary end points included overall survival, acute and chronic toxic effects, and quality of life.METHODSIn this randomized phase 3 trial, we tested whether 6 months of platinum-based chemotherapy plus radiation therapy (chemoradiotherapy) is associated with longer relapse-free survival (primary end point) than six cycles of combination chemotherapy alone in patients with stage III or IVA endometrial carcinoma. Secondary end points included overall survival, acute and chronic toxic effects, and quality of life.Of the 813 patients enrolled, 736 were eligible and were included in the analysis of relapse-free survival; of those patients, 707 received the randomly assigned intervention (346 received chemoradiotherapy and 361 received chemotherapy only). The median follow-up period was 47 months. At 60 months, the Kaplan-Meier estimate of the percentage of patients alive and relapse-free was 59% (95% confidence interval [CI], 53 to 65) in the chemoradiotherapy group and 58% (95% CI, 53 to 64) in the chemotherapy-only group (hazard ratio, 0.90; 90% CI, 0.74 to 1.10). Chemoradiotherapy was associated with a lower 5-year incidence of vaginal recurrence (2% vs. 7%; hazard ratio, 0.36; 95% CI, 0.16 to 0.82) and pelvic and paraaortic lymph-node recurrence (11% vs. 20%; hazard ratio, 0.43; 95% CI, 0.28 to 0.66) than chemotherapy alone, but distant recurrence was more common in association with chemoradiotherapy (27% vs. 21%; hazard ratio, 1.36; 95% CI, 1.00 to 1.86). Grade 3, 4, or 5 adverse events were reported in 202 patients (58%) in the chemoradiotherapy group and 227 patients (63%) in the chemotherapy-only group.RESULTSOf the 813 patients enrolled, 736 were eligible and were included in the analysis of relapse-free survival; of those patients, 707 received the randomly assigned intervention (346 received chemoradiotherapy and 361 received chemotherapy only). The median follow-up period was 47 months. At 60 months, the Kaplan-Meier estimate of the percentage of patients alive and relapse-free was 59% (95% confidence interval [CI], 53 to 65) in the chemoradiotherapy group and 58% (95% CI, 53 to 64) in the chemotherapy-only group (hazard ratio, 0.90; 90% CI, 0.74 to 1.10). Chemoradiotherapy was associated with a lower 5-year incidence of vaginal recurrence (2% vs. 7%; hazard ratio, 0.36; 95% CI, 0.16 to 0.82) and pelvic and paraaortic lymph-node recurrence (11% vs. 20%; hazard ratio, 0.43; 95% CI, 0.28 to 0.66) than chemotherapy alone, but distant recurrence was more common in association with chemoradiotherapy (27% vs. 21%; hazard ratio, 1.36; 95% CI, 1.00 to 1.86). Grade 3, 4, or 5 adverse events were reported in 202 patients (58%) in the chemoradiotherapy group and 227 patients (63%) in the chemotherapy-only group.Chemotherapy plus radiation was not associated with longer relapse-free survival than chemotherapy alone in patients with stage III or IVA endometrial carcinoma. (Funded by the National Cancer Institute; ClinicalTrials.gov number, NCT00942357.).CONCLUSIONSChemotherapy plus radiation was not associated with longer relapse-free survival than chemotherapy alone in patients with stage III or IVA endometrial carcinoma. (Funded by the National Cancer Institute; ClinicalTrials.gov number, NCT00942357.). Stage III or IVA endometrial cancer carries a significant risk of systemic and locoregional recurrence. In this randomized phase 3 trial, we tested whether 6 months of platinum-based chemotherapy plus radiation therapy (chemoradiotherapy) is associated with longer relapse-free survival (primary end point) than six cycles of combination chemotherapy alone in patients with stage III or IVA endometrial carcinoma. Secondary end points included overall survival, acute and chronic toxic effects, and quality of life. Of the 813 patients enrolled, 736 were eligible and were included in the analysis of relapse-free survival; of those patients, 707 received the randomly assigned intervention (346 received chemoradiotherapy and 361 received chemotherapy only). The median follow-up period was 47 months. At 60 months, the Kaplan-Meier estimate of the percentage of patients alive and relapse-free was 59% (95% confidence interval [CI], 53 to 65) in the chemoradiotherapy group and 58% (95% CI, 53 to 64) in the chemotherapy-only group (hazard ratio, 0.90; 90% CI, 0.74 to 1.10). Chemoradiotherapy was associated with a lower 5-year incidence of vaginal recurrence (2% vs. 7%; hazard ratio, 0.36; 95% CI, 0.16 to 0.82) and pelvic and paraaortic lymph-node recurrence (11% vs. 20%; hazard ratio, 0.43; 95% CI, 0.28 to 0.66) than chemotherapy alone, but distant recurrence was more common in association with chemoradiotherapy (27% vs. 21%; hazard ratio, 1.36; 95% CI, 1.00 to 1.86). Grade 3, 4, or 5 adverse events were reported in 202 patients (58%) in the chemoradiotherapy group and 227 patients (63%) in the chemotherapy-only group. Chemotherapy plus radiation was not associated with longer relapse-free survival than chemotherapy alone in patients with stage III or IVA endometrial carcinoma. (Funded by the National Cancer Institute; ClinicalTrials.gov number, NCT00942357.). After a median of nearly 4 years of follow-up, the use of radiotherapy combined with chemotherapy in patients with stage III or IVA endometrial carcinoma was not associated with longer relapse-free survival than the use of chemotherapy alone. |
| Author | Steinhoff, Margaret M Richards, William E Matei, Daniela O’Malley, David M Mutch, David Moxley, Katherine M Matulonis, Ursula A DiSilvestro, Paul A Miller, David S Huang, Helen Q Spirtos, Nick M Kim, Yong M Powell, Matthew A Randall, Marcus E Small, William Nakayama, John Filiaci, Virginia Tewari, Krishnansu S |
| Author_xml | – sequence: 1 givenname: Daniela surname: Matei fullname: Matei, Daniela organization: From Northwestern University (D. Matei) and Loyola University (W.S.) — both in Chicago; NRG Oncology Statistical and Data Center, Roswell Park Comprehensive Cancer Center, Buffalo, NY (V.F., H.Q.H.); University of Kentucky, Lexington (M.E.R.); Washington University School of Medicine, Siteman Cancer Center, St. Louis (D. Mutch, M.A.P.); Women and Infants Hospital in Rhode Island–The Warren Alpert Medical School of Brown University, Providence (M.M.S., P.A.D.); Stephenson Cancer Center Gynecologic Cancers Clinic, University of Oklahoma Health Sciences Center, Oklahoma City (K.M.M.); Asan Medical Center, University of Ulsan, Songpa-gu, Seoul, South Korea (Y.M.K.); Ohio State University, Columbus (D.M.O.); Women’s Cancer Center of Nevada, Las Vegas (N.M.S.); University of California Irvine Medical Center, Irvine (K.S.T.); Lewis Cancer and Research Pavilion at St. Joseph’s–Candler, Savannah, GA (W.E.R.); Case Western Reserve University Hospital, Cleveland (J.N.); Dana–Farber Cancer Institute, Boston (U.A.M.); and the University of Texas Southwestern Medical Center, Dallas (D.S.M.) – sequence: 2 givenname: Virginia surname: Filiaci fullname: Filiaci, Virginia organization: From Northwestern University (D. Matei) and Loyola University (W.S.) — both in Chicago; NRG Oncology Statistical and Data Center, Roswell Park Comprehensive Cancer Center, Buffalo, NY (V.F., H.Q.H.); University of Kentucky, Lexington (M.E.R.); Washington University School of Medicine, Siteman Cancer Center, St. Louis (D. Mutch, M.A.P.); Women and Infants Hospital in Rhode Island–The Warren Alpert Medical School of Brown University, Providence (M.M.S., P.A.D.); Stephenson Cancer Center Gynecologic Cancers Clinic, University of Oklahoma Health Sciences Center, Oklahoma City (K.M.M.); Asan Medical Center, University of Ulsan, Songpa-gu, Seoul, South Korea (Y.M.K.); Ohio State University, Columbus (D.M.O.); Women’s Cancer Center of Nevada, Las Vegas (N.M.S.); University of California Irvine Medical Center, Irvine (K.S.T.); Lewis Cancer and Research Pavilion at St. Joseph’s–Candler, Savannah, GA (W.E.R.); Case Western Reserve University Hospital, Cleveland (J.N.); Dana–Farber Cancer Institute, Boston (U.A.M.); and the University of Texas Southwestern Medical Center, Dallas (D.S.M.) – sequence: 3 givenname: Marcus E surname: Randall fullname: Randall, Marcus E organization: From Northwestern University (D. Matei) and Loyola University (W.S.) — both in Chicago; NRG Oncology Statistical and Data Center, Roswell Park Comprehensive Cancer Center, Buffalo, NY (V.F., H.Q.H.); University of Kentucky, Lexington (M.E.R.); Washington University School of Medicine, Siteman Cancer Center, St. Louis (D. Mutch, M.A.P.); Women and Infants Hospital in Rhode Island–The Warren Alpert Medical School of Brown University, Providence (M.M.S., P.A.D.); Stephenson Cancer Center Gynecologic Cancers Clinic, University of Oklahoma Health Sciences Center, Oklahoma City (K.M.M.); Asan Medical Center, University of Ulsan, Songpa-gu, Seoul, South Korea (Y.M.K.); Ohio State University, Columbus (D.M.O.); Women’s Cancer Center of Nevada, Las Vegas (N.M.S.); University of California Irvine Medical Center, Irvine (K.S.T.); Lewis Cancer and Research Pavilion at St. Joseph’s–Candler, Savannah, GA (W.E.R.); Case Western Reserve University Hospital, Cleveland (J.N.); Dana–Farber Cancer Institute, Boston (U.A.M.); and the University of Texas Southwestern Medical Center, Dallas (D.S.M.) – sequence: 4 givenname: David surname: Mutch fullname: Mutch, David organization: From Northwestern University (D. Matei) and Loyola University (W.S.) — both in Chicago; NRG Oncology Statistical and Data Center, Roswell Park Comprehensive Cancer Center, Buffalo, NY (V.F., H.Q.H.); University of Kentucky, Lexington (M.E.R.); Washington University School of Medicine, Siteman Cancer Center, St. Louis (D. Mutch, M.A.P.); Women and Infants Hospital in Rhode Island–The Warren Alpert Medical School of Brown University, Providence (M.M.S., P.A.D.); Stephenson Cancer Center Gynecologic Cancers Clinic, University of Oklahoma Health Sciences Center, Oklahoma City (K.M.M.); Asan Medical Center, University of Ulsan, Songpa-gu, Seoul, South Korea (Y.M.K.); Ohio State University, Columbus (D.M.O.); Women’s Cancer Center of Nevada, Las Vegas (N.M.S.); University of California Irvine Medical Center, Irvine (K.S.T.); Lewis Cancer and Research Pavilion at St. Joseph’s–Candler, Savannah, GA (W.E.R.); Case Western Reserve University Hospital, Cleveland (J.N.); Dana–Farber Cancer Institute, Boston (U.A.M.); and the University of Texas Southwestern Medical Center, Dallas (D.S.M.) – sequence: 5 givenname: Margaret M surname: Steinhoff fullname: Steinhoff, Margaret M organization: From Northwestern University (D. Matei) and Loyola University (W.S.) — both in Chicago; NRG Oncology Statistical and Data Center, Roswell Park Comprehensive Cancer Center, Buffalo, NY (V.F., H.Q.H.); University of Kentucky, Lexington (M.E.R.); Washington University School of Medicine, Siteman Cancer Center, St. Louis (D. Mutch, M.A.P.); Women and Infants Hospital in Rhode Island–The Warren Alpert Medical School of Brown University, Providence (M.M.S., P.A.D.); Stephenson Cancer Center Gynecologic Cancers Clinic, University of Oklahoma Health Sciences Center, Oklahoma City (K.M.M.); Asan Medical Center, University of Ulsan, Songpa-gu, Seoul, South Korea (Y.M.K.); Ohio State University, Columbus (D.M.O.); Women’s Cancer Center of Nevada, Las Vegas (N.M.S.); University of California Irvine Medical Center, Irvine (K.S.T.); Lewis Cancer and Research Pavilion at St. Joseph’s–Candler, Savannah, GA (W.E.R.); Case Western Reserve University Hospital, Cleveland (J.N.); Dana–Farber Cancer Institute, Boston (U.A.M.); and the University of Texas Southwestern Medical Center, Dallas (D.S.M.) – sequence: 6 givenname: Paul A surname: DiSilvestro fullname: DiSilvestro, Paul A organization: From Northwestern University (D. Matei) and Loyola University (W.S.) — both in Chicago; NRG Oncology Statistical and Data Center, Roswell Park Comprehensive Cancer Center, Buffalo, NY (V.F., H.Q.H.); University of Kentucky, Lexington (M.E.R.); Washington University School of Medicine, Siteman Cancer Center, St. Louis (D. Mutch, M.A.P.); Women and Infants Hospital in Rhode Island–The Warren Alpert Medical School of Brown University, Providence (M.M.S., P.A.D.); Stephenson Cancer Center Gynecologic Cancers Clinic, University of Oklahoma Health Sciences Center, Oklahoma City (K.M.M.); Asan Medical Center, University of Ulsan, Songpa-gu, Seoul, South Korea (Y.M.K.); Ohio State University, Columbus (D.M.O.); Women’s Cancer Center of Nevada, Las Vegas (N.M.S.); University of California Irvine Medical Center, Irvine (K.S.T.); Lewis Cancer and Research Pavilion at St. Joseph’s–Candler, Savannah, GA (W.E.R.); Case Western Reserve University Hospital, Cleveland (J.N.); Dana–Farber Cancer Institute, Boston (U.A.M.); and the University of Texas Southwestern Medical Center, Dallas (D.S.M.) – sequence: 7 givenname: Katherine M surname: Moxley fullname: Moxley, Katherine M organization: From Northwestern University (D. Matei) and Loyola University (W.S.) — both in Chicago; NRG Oncology Statistical and Data Center, Roswell Park Comprehensive Cancer Center, Buffalo, NY (V.F., H.Q.H.); University of Kentucky, Lexington (M.E.R.); Washington University School of Medicine, Siteman Cancer Center, St. Louis (D. Mutch, M.A.P.); Women and Infants Hospital in Rhode Island–The Warren Alpert Medical School of Brown University, Providence (M.M.S., P.A.D.); Stephenson Cancer Center Gynecologic Cancers Clinic, University of Oklahoma Health Sciences Center, Oklahoma City (K.M.M.); Asan Medical Center, University of Ulsan, Songpa-gu, Seoul, South Korea (Y.M.K.); Ohio State University, Columbus (D.M.O.); Women’s Cancer Center of Nevada, Las Vegas (N.M.S.); University of California Irvine Medical Center, Irvine (K.S.T.); Lewis Cancer and Research Pavilion at St. Joseph’s–Candler, Savannah, GA (W.E.R.); Case Western Reserve University Hospital, Cleveland (J.N.); Dana–Farber Cancer Institute, Boston (U.A.M.); and the University of Texas Southwestern Medical Center, Dallas (D.S.M.) – sequence: 8 givenname: Yong M surname: Kim fullname: Kim, Yong M organization: From Northwestern University (D. Matei) and Loyola University (W.S.) — both in Chicago; NRG Oncology Statistical and Data Center, Roswell Park Comprehensive Cancer Center, Buffalo, NY (V.F., H.Q.H.); University of Kentucky, Lexington (M.E.R.); Washington University School of Medicine, Siteman Cancer Center, St. Louis (D. Mutch, M.A.P.); Women and Infants Hospital in Rhode Island–The Warren Alpert Medical School of Brown University, Providence (M.M.S., P.A.D.); Stephenson Cancer Center Gynecologic Cancers Clinic, University of Oklahoma Health Sciences Center, Oklahoma City (K.M.M.); Asan Medical Center, University of Ulsan, Songpa-gu, Seoul, South Korea (Y.M.K.); Ohio State University, Columbus (D.M.O.); Women’s Cancer Center of Nevada, Las Vegas (N.M.S.); University of California Irvine Medical Center, Irvine (K.S.T.); Lewis Cancer and Research Pavilion at St. Joseph’s–Candler, Savannah, GA (W.E.R.); Case Western Reserve University Hospital, Cleveland (J.N.); Dana–Farber Cancer Institute, Boston (U.A.M.); and the University of Texas Southwestern Medical Center, Dallas (D.S.M.) – sequence: 9 givenname: Matthew A surname: Powell fullname: Powell, Matthew A organization: From Northwestern University (D. Matei) and Loyola University (W.S.) — both in Chicago; NRG Oncology Statistical and Data Center, Roswell Park Comprehensive Cancer Center, Buffalo, NY (V.F., H.Q.H.); University of Kentucky, Lexington (M.E.R.); Washington University School of Medicine, Siteman Cancer Center, St. Louis (D. Mutch, M.A.P.); Women and Infants Hospital in Rhode Island–The Warren Alpert Medical School of Brown University, Providence (M.M.S., P.A.D.); Stephenson Cancer Center Gynecologic Cancers Clinic, University of Oklahoma Health Sciences Center, Oklahoma City (K.M.M.); Asan Medical Center, University of Ulsan, Songpa-gu, Seoul, South Korea (Y.M.K.); Ohio State University, Columbus (D.M.O.); Women’s Cancer Center of Nevada, Las Vegas (N.M.S.); University of California Irvine Medical Center, Irvine (K.S.T.); Lewis Cancer and Research Pavilion at St. Joseph’s–Candler, Savannah, GA (W.E.R.); Case Western Reserve University Hospital, Cleveland (J.N.); Dana–Farber Cancer Institute, Boston (U.A.M.); and the University of Texas Southwestern Medical Center, Dallas (D.S.M.) – sequence: 10 givenname: David M surname: O’Malley fullname: O’Malley, David M organization: From Northwestern University (D. Matei) and Loyola University (W.S.) — both in Chicago; NRG Oncology Statistical and Data Center, Roswell Park Comprehensive Cancer Center, Buffalo, NY (V.F., H.Q.H.); University of Kentucky, Lexington (M.E.R.); Washington University School of Medicine, Siteman Cancer Center, St. Louis (D. Mutch, M.A.P.); Women and Infants Hospital in Rhode Island–The Warren Alpert Medical School of Brown University, Providence (M.M.S., P.A.D.); Stephenson Cancer Center Gynecologic Cancers Clinic, University of Oklahoma Health Sciences Center, Oklahoma City (K.M.M.); Asan Medical Center, University of Ulsan, Songpa-gu, Seoul, South Korea (Y.M.K.); Ohio State University, Columbus (D.M.O.); Women’s Cancer Center of Nevada, Las Vegas (N.M.S.); University of California Irvine Medical Center, Irvine (K.S.T.); Lewis Cancer and Research Pavilion at St. Joseph’s–Candler, Savannah, GA (W.E.R.); Case Western Reserve University Hospital, Cleveland (J.N.); Dana–Farber Cancer Institute, Boston (U.A.M.); and the University of Texas Southwestern Medical Center, Dallas (D.S.M.) – sequence: 11 givenname: Nick M surname: Spirtos fullname: Spirtos, Nick M organization: From Northwestern University (D. Matei) and Loyola University (W.S.) — both in Chicago; NRG Oncology Statistical and Data Center, Roswell Park Comprehensive Cancer Center, Buffalo, NY (V.F., H.Q.H.); University of Kentucky, Lexington (M.E.R.); Washington University School of Medicine, Siteman Cancer Center, St. Louis (D. Mutch, M.A.P.); Women and Infants Hospital in Rhode Island–The Warren Alpert Medical School of Brown University, Providence (M.M.S., P.A.D.); Stephenson Cancer Center Gynecologic Cancers Clinic, University of Oklahoma Health Sciences Center, Oklahoma City (K.M.M.); Asan Medical Center, University of Ulsan, Songpa-gu, Seoul, South Korea (Y.M.K.); Ohio State University, Columbus (D.M.O.); Women’s Cancer Center of Nevada, Las Vegas (N.M.S.); University of California Irvine Medical Center, Irvine (K.S.T.); Lewis Cancer and Research Pavilion at St. Joseph’s–Candler, Savannah, GA (W.E.R.); Case Western Reserve University Hospital, Cleveland (J.N.); Dana–Farber Cancer Institute, Boston (U.A.M.); and the University of Texas Southwestern Medical Center, Dallas (D.S.M.) – sequence: 12 givenname: William surname: Small fullname: Small, William organization: From Northwestern University (D. Matei) and Loyola University (W.S.) — both in Chicago; NRG Oncology Statistical and Data Center, Roswell Park Comprehensive Cancer Center, Buffalo, NY (V.F., H.Q.H.); University of Kentucky, Lexington (M.E.R.); Washington University School of Medicine, Siteman Cancer Center, St. Louis (D. Mutch, M.A.P.); Women and Infants Hospital in Rhode Island–The Warren Alpert Medical School of Brown University, Providence (M.M.S., P.A.D.); Stephenson Cancer Center Gynecologic Cancers Clinic, University of Oklahoma Health Sciences Center, Oklahoma City (K.M.M.); Asan Medical Center, University of Ulsan, Songpa-gu, Seoul, South Korea (Y.M.K.); Ohio State University, Columbus (D.M.O.); Women’s Cancer Center of Nevada, Las Vegas (N.M.S.); University of California Irvine Medical Center, Irvine (K.S.T.); Lewis Cancer and Research Pavilion at St. Joseph’s–Candler, Savannah, GA (W.E.R.); Case Western Reserve University Hospital, Cleveland (J.N.); Dana–Farber Cancer Institute, Boston (U.A.M.); and the University of Texas Southwestern Medical Center, Dallas (D.S.M.) – sequence: 13 givenname: Krishnansu S surname: Tewari fullname: Tewari, Krishnansu S organization: From Northwestern University (D. Matei) and Loyola University (W.S.) — both in Chicago; NRG Oncology Statistical and Data Center, Roswell Park Comprehensive Cancer Center, Buffalo, NY (V.F., H.Q.H.); University of Kentucky, Lexington (M.E.R.); Washington University School of Medicine, Siteman Cancer Center, St. Louis (D. Mutch, M.A.P.); Women and Infants Hospital in Rhode Island–The Warren Alpert Medical School of Brown University, Providence (M.M.S., P.A.D.); Stephenson Cancer Center Gynecologic Cancers Clinic, University of Oklahoma Health Sciences Center, Oklahoma City (K.M.M.); Asan Medical Center, University of Ulsan, Songpa-gu, Seoul, South Korea (Y.M.K.); Ohio State University, Columbus (D.M.O.); Women’s Cancer Center of Nevada, Las Vegas (N.M.S.); University of California Irvine Medical Center, Irvine (K.S.T.); Lewis Cancer and Research Pavilion at St. Joseph’s–Candler, Savannah, GA (W.E.R.); Case Western Reserve University Hospital, Cleveland (J.N.); Dana–Farber Cancer Institute, Boston (U.A.M.); and the University of Texas Southwestern Medical Center, Dallas (D.S.M.) – sequence: 14 givenname: William E surname: Richards fullname: Richards, William E organization: From Northwestern University (D. Matei) and Loyola University (W.S.) — both in Chicago; NRG Oncology Statistical and Data Center, Roswell Park Comprehensive Cancer Center, Buffalo, NY (V.F., H.Q.H.); University of Kentucky, Lexington (M.E.R.); Washington University School of Medicine, Siteman Cancer Center, St. Louis (D. Mutch, M.A.P.); Women and Infants Hospital in Rhode Island–The Warren Alpert Medical School of Brown University, Providence (M.M.S., P.A.D.); Stephenson Cancer Center Gynecologic Cancers Clinic, University of Oklahoma Health Sciences Center, Oklahoma City (K.M.M.); Asan Medical Center, University of Ulsan, Songpa-gu, Seoul, South Korea (Y.M.K.); Ohio State University, Columbus (D.M.O.); Women’s Cancer Center of Nevada, Las Vegas (N.M.S.); University of California Irvine Medical Center, Irvine (K.S.T.); Lewis Cancer and Research Pavilion at St. Joseph’s–Candler, Savannah, GA (W.E.R.); Case Western Reserve University Hospital, Cleveland (J.N.); Dana–Farber Cancer Institute, Boston (U.A.M.); and the University of Texas Southwestern Medical Center, Dallas (D.S.M.) – sequence: 15 givenname: John surname: Nakayama fullname: Nakayama, John organization: From Northwestern University (D. Matei) and Loyola University (W.S.) — both in Chicago; NRG Oncology Statistical and Data Center, Roswell Park Comprehensive Cancer Center, Buffalo, NY (V.F., H.Q.H.); University of Kentucky, Lexington (M.E.R.); Washington University School of Medicine, Siteman Cancer Center, St. Louis (D. Mutch, M.A.P.); Women and Infants Hospital in Rhode Island–The Warren Alpert Medical School of Brown University, Providence (M.M.S., P.A.D.); Stephenson Cancer Center Gynecologic Cancers Clinic, University of Oklahoma Health Sciences Center, Oklahoma City (K.M.M.); Asan Medical Center, University of Ulsan, Songpa-gu, Seoul, South Korea (Y.M.K.); Ohio State University, Columbus (D.M.O.); Women’s Cancer Center of Nevada, Las Vegas (N.M.S.); University of California Irvine Medical Center, Irvine (K.S.T.); Lewis Cancer and Research Pavilion at St. Joseph’s–Candler, Savannah, GA (W.E.R.); Case Western Reserve University Hospital, Cleveland (J.N.); Dana–Farber Cancer Institute, Boston (U.A.M.); and the University of Texas Southwestern Medical Center, Dallas (D.S.M.) – sequence: 16 givenname: Ursula A surname: Matulonis fullname: Matulonis, Ursula A organization: From Northwestern University (D. Matei) and Loyola University (W.S.) — both in Chicago; NRG Oncology Statistical and Data Center, Roswell Park Comprehensive Cancer Center, Buffalo, NY (V.F., H.Q.H.); University of Kentucky, Lexington (M.E.R.); Washington University School of Medicine, Siteman Cancer Center, St. Louis (D. Mutch, M.A.P.); Women and Infants Hospital in Rhode Island–The Warren Alpert Medical School of Brown University, Providence (M.M.S., P.A.D.); Stephenson Cancer Center Gynecologic Cancers Clinic, University of Oklahoma Health Sciences Center, Oklahoma City (K.M.M.); Asan Medical Center, University of Ulsan, Songpa-gu, Seoul, South Korea (Y.M.K.); Ohio State University, Columbus (D.M.O.); Women’s Cancer Center of Nevada, Las Vegas (N.M.S.); University of California Irvine Medical Center, Irvine (K.S.T.); Lewis Cancer and Research Pavilion at St. Joseph’s–Candler, Savannah, GA (W.E.R.); Case Western Reserve University Hospital, Cleveland (J.N.); Dana–Farber Cancer Institute, Boston (U.A.M.); and the University of Texas Southwestern Medical Center, Dallas (D.S.M.) – sequence: 17 givenname: Helen Q surname: Huang fullname: Huang, Helen Q organization: From Northwestern University (D. Matei) and Loyola University (W.S.) — both in Chicago; NRG Oncology Statistical and Data Center, Roswell Park Comprehensive Cancer Center, Buffalo, NY (V.F., H.Q.H.); University of Kentucky, Lexington (M.E.R.); Washington University School of Medicine, Siteman Cancer Center, St. Louis (D. Mutch, M.A.P.); Women and Infants Hospital in Rhode Island–The Warren Alpert Medical School of Brown University, Providence (M.M.S., P.A.D.); Stephenson Cancer Center Gynecologic Cancers Clinic, University of Oklahoma Health Sciences Center, Oklahoma City (K.M.M.); Asan Medical Center, University of Ulsan, Songpa-gu, Seoul, South Korea (Y.M.K.); Ohio State University, Columbus (D.M.O.); Women’s Cancer Center of Nevada, Las Vegas (N.M.S.); University of California Irvine Medical Center, Irvine (K.S.T.); Lewis Cancer and Research Pavilion at St. Joseph’s–Candler, Savannah, GA (W.E.R.); Case Western Reserve University Hospital, Cleveland (J.N.); Dana–Farber Cancer Institute, Boston (U.A.M.); and the University of Texas Southwestern Medical Center, Dallas (D.S.M.) – sequence: 18 givenname: David S surname: Miller fullname: Miller, David S organization: From Northwestern University (D. Matei) and Loyola University (W.S.) — both in Chicago; NRG Oncology Statistical and Data Center, Roswell Park Comprehensive Cancer Center, Buffalo, NY (V.F., H.Q.H.); University of Kentucky, Lexington (M.E.R.); Washington University School of Medicine, Siteman Cancer Center, St. Louis (D. Mutch, M.A.P.); Women and Infants Hospital in Rhode Island–The Warren Alpert Medical School of Brown University, Providence (M.M.S., P.A.D.); Stephenson Cancer Center Gynecologic Cancers Clinic, University of Oklahoma Health Sciences Center, Oklahoma City (K.M.M.); Asan Medical Center, University of Ulsan, Songpa-gu, Seoul, South Korea (Y.M.K.); Ohio State University, Columbus (D.M.O.); Women’s Cancer Center of Nevada, Las Vegas (N.M.S.); University of California Irvine Medical Center, Irvine (K.S.T.); Lewis Cancer and Research Pavilion at St. Joseph’s–Candler, Savannah, GA (W.E.R.); Case Western Reserve University Hospital, Cleveland (J.N.); Dana–Farber Cancer Institute, Boston (U.A.M.); and the University of Texas Southwestern Medical Center, Dallas (D.S.M.) |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31189035$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1kc1rGzEQxUVJaZy0x17LQinkso1m9WHpUjDG6QduC6U9i7FWW8vsSq60G_B_XyVOShOIQAhGv3m8eXNGTkIMjpDXQN8DFfLy2-rL14iggJX7jMxAMFZzTuUJmVHaqJrPNTslZznvaDnA9QtyygCUpkzMyHrR7qZrDGO13LohjluXcH-o9v2Uqx_Yehx9DFUXU7WOFvv-UC3aglvXVqvQxsGNyWNfLW9K6SV53mGf3au795z8ulr9XH6q198_fl4u1rXlXIw1A6osCOEksgah0U43HDfaKWuVBKQa7ZwKKlTxj8A7iVq2rWR006CCjp2TD0fd_bQZXGtdGBP2Zp_8gOlgInrz8Cf4rfkdr43UXFEqi8DFnUCKfyaXRzP4bF3fY3BxyqZpBADldC4K-vYRuotTCmW8QjHdSAWaF-rN_47-WbkPugDsCNgUc06uM9aPt-EWg743QM3NOs2DdZau-lHXvfBT_LsjPwzZBLcbnuD-Al56q5Q |
| CitedBy_id | crossref_primary_10_1055_a_2571_5912 crossref_primary_10_1038_s41698_025_01063_9 crossref_primary_10_1200_JCO_25_00473 crossref_primary_10_3390_ijms25147742 crossref_primary_10_1016_j_ejso_2024_107985 crossref_primary_10_1111_ajt_16318 crossref_primary_10_1055_a_2481_0958 crossref_primary_10_3390_ijms241411489 crossref_primary_10_1016_j_currproblcancer_2022_100895 crossref_primary_10_1007_s00066_020_01735_4 crossref_primary_10_1016_j_clon_2020_08_009 crossref_primary_10_3390_ijerph16142561 crossref_primary_10_1186_s12935_023_02966_y crossref_primary_10_3389_fonc_2020_01175 crossref_primary_10_1136_ijgc_2022_003727 crossref_primary_10_1016_j_ygyno_2022_04_007 crossref_primary_10_3390_cancers13246275 crossref_primary_10_3390_cancers15215155 crossref_primary_10_1007_s00066_021_01862_6 crossref_primary_10_32708_uutfd_1028896 crossref_primary_10_1097_og9_0000000000000010 crossref_primary_10_1016_j_yao_2022_02_009 crossref_primary_10_3389_fonc_2022_1030246 crossref_primary_10_1038_s41571_024_00934_7 crossref_primary_10_1016_j_prro_2023_05_009 crossref_primary_10_3390_cancers16244240 crossref_primary_10_3390_antiox14030369 crossref_primary_10_1016_j_ygyno_2020_01_012 crossref_primary_10_1053_j_seminoncol_2020_04_006 crossref_primary_10_1016_j_ygyno_2024_01_017 crossref_primary_10_1016_j_ygyno_2024_08_019 crossref_primary_10_1136_ijgc_2022_003717 crossref_primary_10_1016_j_ygyno_2024_01_013 crossref_primary_10_1016_j_ijrobp_2024_01_010 crossref_primary_10_1016_j_ygyno_2020_07_105 crossref_primary_10_1177_10732748221115288 crossref_primary_10_3390_cancers13092052 crossref_primary_10_1186_s12885_022_10193_3 crossref_primary_10_1155_2022_1418232 crossref_primary_10_14423_SMJ_0000000000001305 crossref_primary_10_1016_S1470_2045_24_00192_X crossref_primary_10_1186_s13046_023_02834_7 crossref_primary_10_1007_s00432_020_03339_y crossref_primary_10_1007_s43032_024_01544_5 crossref_primary_10_1016_j_canrad_2024_10_002 crossref_primary_10_1007_s00330_023_09685_y crossref_primary_10_1016_j_ygyno_2021_06_031 crossref_primary_10_1016_j_annonc_2024_05_546 crossref_primary_10_1016_j_radonc_2020_11_018 crossref_primary_10_1055_a_1332_8347 crossref_primary_10_1016_j_prro_2021_10_002 crossref_primary_10_1016_j_annonc_2024_09_006 crossref_primary_10_1136_ijgc_2021_002459 crossref_primary_10_1016_j_ygyno_2023_11_012 crossref_primary_10_1177_10732748241299072 crossref_primary_10_3802_jgo_2025_36_e79 crossref_primary_10_1016_j_gore_2025_101756 crossref_primary_10_1007_s12094_023_03355_7 crossref_primary_10_1136_ijgc_2024_005567 crossref_primary_10_3390_cancers11121885 crossref_primary_10_1155_2022_4621240 crossref_primary_10_1097_COC_0000000000000742 crossref_primary_10_3390_cancers16020362 crossref_primary_10_1016_S1470_2045_19_30395_X crossref_primary_10_1038_s41598_024_74840_4 crossref_primary_10_1016_j_ajog_2021_08_011 crossref_primary_10_1016_j_ygyno_2023_11_024 crossref_primary_10_1016_j_ejso_2022_09_004 crossref_primary_10_1016_j_ygyno_2020_12_002 crossref_primary_10_1016_j_ygyno_2020_09_033 crossref_primary_10_1007_s00066_020_01592_1 crossref_primary_10_1038_s41598_024_53172_3 crossref_primary_10_1016_j_mcp_2020_101572 crossref_primary_10_1136_ijgc_2020_001199 crossref_primary_10_1016_j_gore_2021_100754 crossref_primary_10_1016_j_ygyno_2020_07_010 crossref_primary_10_1002_onco_13934 crossref_primary_10_1016_j_tjog_2025_04_007 crossref_primary_10_1111_cts_13642 crossref_primary_10_3390_cancers15225322 crossref_primary_10_1136_ijgc_2020_002158 crossref_primary_10_1016_S1470_2045_19_30416_4 crossref_primary_10_1007_s10147_025_02843_w crossref_primary_10_3390_cancers16061172 crossref_primary_10_1136_ijgc_2023_004617 crossref_primary_10_1136_ijgc_2021_003087 crossref_primary_10_1002_ijgo_70280 crossref_primary_10_1136_ijgc_2021_002554 crossref_primary_10_1016_j_ygyno_2021_11_007 crossref_primary_10_1016_j_ijrobp_2021_05_002 crossref_primary_10_1097_MD_0000000000029156 crossref_primary_10_1186_s13550_025_01235_5 crossref_primary_10_1186_s13014_020_01523_5 crossref_primary_10_1016_j_ygyno_2019_06_020 crossref_primary_10_1016_S0140_6736_22_00323_3 crossref_primary_10_3390_cancers12071906 crossref_primary_10_1097_CCO_0000000000000777 crossref_primary_10_1016_j_ygyno_2025_02_020 crossref_primary_10_1016_j_prro_2021_04_006 crossref_primary_10_1016_j_ijgc_2025_101658 crossref_primary_10_1097_COC_0000000000000717 crossref_primary_10_1016_j_jmig_2020_12_025 crossref_primary_10_1093_jjco_hyaa071 crossref_primary_10_1002_smll_202300096 crossref_primary_10_1002_smtd_202200570 crossref_primary_10_1016_j_ijgc_2025_101773 crossref_primary_10_3390_cancers15143673 crossref_primary_10_1016_j_gore_2024_101469 crossref_primary_10_62347_LIZG3616 crossref_primary_10_1016_j_ctarc_2022_100581 crossref_primary_10_3390_jcm10010093 crossref_primary_10_1016_j_clon_2022_11_001 crossref_primary_10_1136_ijgc_2019_000643 crossref_primary_10_1016_j_ajog_2020_02_041 crossref_primary_10_1016_j_tjog_2024_12_027 crossref_primary_10_1016_j_ygyno_2020_03_016 crossref_primary_10_3390_biology10090845 crossref_primary_10_3390_jcm11216462 crossref_primary_10_1016_j_brachy_2021_02_007 crossref_primary_10_1055_a_2605_4474 crossref_primary_10_1136_bmj_2024_080978 crossref_primary_10_1186_s12967_021_03086_9 crossref_primary_10_3389_fonc_2024_1480102 crossref_primary_10_3390_cancers14184500 crossref_primary_10_1186_s12905_022_01667_4 crossref_primary_10_1016_j_ygyno_2021_09_008 crossref_primary_10_1016_j_prro_2024_05_010 crossref_primary_10_1016_j_ygyno_2023_05_069 crossref_primary_10_1016_j_ygyno_2025_03_051 crossref_primary_10_57264_cer_2023_0159 crossref_primary_10_1016_j_ijrobp_2025_03_010 crossref_primary_10_1016_j_ygyno_2021_09_005 crossref_primary_10_1016_j_canrad_2023_06_012 crossref_primary_10_1016_j_ygyno_2022_02_024 crossref_primary_10_1016_j_critrevonc_2020_103016 crossref_primary_10_1016_j_ijrobp_2021_02_055 crossref_primary_10_1016_j_ygyno_2022_02_023 crossref_primary_10_1097_GCO_0000000000001055 crossref_primary_10_1002_ijc_32740 crossref_primary_10_1016_j_ejca_2022_04_038 crossref_primary_10_1245_s10434_021_09900_4 crossref_primary_10_3389_fonc_2021_612450 crossref_primary_10_3390_cancers12123613 crossref_primary_10_1016_j_ygyno_2021_11_021 crossref_primary_10_1016_S0007_4551_23_00331_4 crossref_primary_10_3389_fonc_2022_946113 crossref_primary_10_1016_j_ijrobp_2024_12_008 crossref_primary_10_3390_cancers13102487 crossref_primary_10_1016_j_bulcan_2022_11_003 crossref_primary_10_1016_j_ygyno_2023_03_003 crossref_primary_10_1080_14737140_2020_1782750 crossref_primary_10_1016_j_canep_2024_102664 crossref_primary_10_1136_ijgc_2023_004649 crossref_primary_10_3389_fcell_2021_702451 crossref_primary_10_1007_s11764_023_01460_8 crossref_primary_10_1016_j_ijgc_2025_101672 crossref_primary_10_1080_14656566_2019_1654996 crossref_primary_10_1007_s00280_019_04027_6 crossref_primary_10_1016_j_jogoh_2021_102063 crossref_primary_10_1016_j_ijgc_2025_101671 crossref_primary_10_12998_wjcc_v11_i23_5447 crossref_primary_10_1007_s00428_020_03007_z crossref_primary_10_1055_a_2066_2068 crossref_primary_10_1007_s40487_025_00352_4 crossref_primary_10_1007_s15004_021_8783_7 crossref_primary_10_1136_ijgc_2020_001709 crossref_primary_10_3389_fonc_2021_634857 crossref_primary_10_3389_fonc_2024_1334541 crossref_primary_10_7717_peerj_14420 crossref_primary_10_1136_ijgc_2021_002753 crossref_primary_10_1016_j_hoc_2019_08_018 crossref_primary_10_1016_j_ygyno_2021_04_006 crossref_primary_10_1016_j_ygyno_2022_11_031 crossref_primary_10_1097_COC_0000000000000927 crossref_primary_10_1136_ijgc_2020_001822 crossref_primary_10_1177_15330338231208610 crossref_primary_10_1002_jso_25797 crossref_primary_10_3389_fonc_2023_1271821 crossref_primary_10_3390_cancers16071346 crossref_primary_10_1111_1754_9485_13107 crossref_primary_10_1136_ijgc_2020_002230 crossref_primary_10_1016_j_ijgc_2025_102034 crossref_primary_10_1016_j_jval_2024_09_018 crossref_primary_10_1111_jog_15238 crossref_primary_10_1111_ajco_14188 crossref_primary_10_1038_s41572_021_00324_8 crossref_primary_10_1186_s12905_023_02429_6 crossref_primary_10_1016_j_ejca_2020_04_012 crossref_primary_10_1186_s13048_025_01630_5 crossref_primary_10_1016_j_ejogrb_2022_02_003 crossref_primary_10_1002_ijgo_13866 crossref_primary_10_1038_s41598_023_33748_1 crossref_primary_10_1016_j_ygyno_2023_04_010 crossref_primary_10_1007_s12094_022_02799_7 crossref_primary_10_1016_j_ygyno_2022_11_022 crossref_primary_10_1016_j_ijgc_2024_100027 crossref_primary_10_1016_j_prro_2022_09_002 crossref_primary_10_1136_ijgc_2022_003673 crossref_primary_10_1097_AOG_0000000000006080 crossref_primary_10_1007_s00432_020_03356_x crossref_primary_10_1007_s15013_022_5096_3 crossref_primary_10_1136_ijgc_2021_002884 crossref_primary_10_1097_MD_0000000000026551 crossref_primary_10_1111_jog_14277 crossref_primary_10_1016_j_ajog_2021_05_007 crossref_primary_10_1016_j_clon_2021_04_013 crossref_primary_10_1016_S1470_2045_25_00379_1 crossref_primary_10_1007_s11596_021_2437_8 crossref_primary_10_3390_cancers13061367 crossref_primary_10_1186_s12885_022_10482_x crossref_primary_10_1016_j_ygyno_2021_01_008 crossref_primary_10_1016_j_ygyno_2020_10_017 crossref_primary_10_1097_COC_0000000000001205 crossref_primary_10_1016_j_ctarc_2022_100631 crossref_primary_10_1002_pro6_1110 crossref_primary_10_1016_j_annonc_2024_08_2242 crossref_primary_10_1136_ijgc_2023_004838 crossref_primary_10_3390_ijerph17165941 crossref_primary_10_1097_PGP_0000000000000994 crossref_primary_10_1007_s00129_019_04526_w crossref_primary_10_1016_j_ajog_2022_03_004 crossref_primary_10_1016_j_ygyno_2025_01_006 crossref_primary_10_1016_j_radcr_2022_03_096 crossref_primary_10_1016_j_ygyno_2021_04_029 crossref_primary_10_1038_s41598_023_31486_y crossref_primary_10_1056_NEJMra1514010 crossref_primary_10_3390_jcm12083014 crossref_primary_10_2147_IJN_S441418 crossref_primary_10_3390_biology12070982 crossref_primary_10_1007_s40944_021_00595_9 crossref_primary_10_3390_ijms232416014 crossref_primary_10_1080_21655979_2021_1947631 crossref_primary_10_1007_s40944_019_0335_9 crossref_primary_10_3390_cancers13163988 crossref_primary_10_1016_j_ygyno_2020_06_486 crossref_primary_10_1021_acs_molpharmaceut_5c00778 crossref_primary_10_1016_j_ygyno_2019_11_002 crossref_primary_10_1007_s00129_022_04959_w crossref_primary_10_1016_j_clinthera_2023_07_025 crossref_primary_10_1016_j_apmt_2022_101584 crossref_primary_10_1039_D4SC08796H crossref_primary_10_1136_ijgc_2023_005017 crossref_primary_10_2147_RMHP_S481880 crossref_primary_10_1007_s11864_023_01169_x crossref_primary_10_1016_j_ygyno_2020_07_098 crossref_primary_10_1055_a_2145_1545 crossref_primary_10_1016_j_brachy_2024_06_005 crossref_primary_10_1080_14656566_2022_2157207 crossref_primary_10_1089_dna_2019_4944 crossref_primary_10_1016_j_cej_2022_137321 crossref_primary_10_1016_j_annonc_2022_05_009 crossref_primary_10_3389_fonc_2023_1035511 crossref_primary_10_1016_j_prro_2023_06_005 crossref_primary_10_1016_j_ijrobp_2024_11_071 crossref_primary_10_1111_jog_70042 crossref_primary_10_1002_ijgo_70326 crossref_primary_10_1002_mco2_427 crossref_primary_10_1016_j_ijgc_2025_102119 crossref_primary_10_1016_j_ijrobp_2022_12_033 crossref_primary_10_1007_s40944_020_00386_8 crossref_primary_10_1038_s41598_023_47419_8 crossref_primary_10_3389_fendo_2022_989063 crossref_primary_10_3390_cancers12092436 crossref_primary_10_1136_ijgc_2023_004472 crossref_primary_10_1186_s12885_022_10437_2 crossref_primary_10_1007_s11912_022_01327_8 crossref_primary_10_1016_j_ygyno_2024_10_021 crossref_primary_10_3390_cancers16040770 crossref_primary_10_1016_j_ejso_2020_10_032 crossref_primary_10_3390_diagnostics10060373 crossref_primary_10_1002_cam4_6276 crossref_primary_10_1016_j_ygyno_2020_12_021 crossref_primary_10_1136_ijgc_2019_000807 crossref_primary_10_1245_s10434_019_08045_9 crossref_primary_10_3390_cancers15215123 crossref_primary_10_1016_j_ygyno_2019_09_016 crossref_primary_10_1016_j_ygyno_2022_09_014 crossref_primary_10_3390_cancers12092577 crossref_primary_10_1136_ijgc_2024_005772 crossref_primary_10_2147_IJWH_S499435 crossref_primary_10_3389_fphar_2019_01658 crossref_primary_10_3390_ijms24021675 crossref_primary_10_1016_j_ygyno_2020_11_012 crossref_primary_10_1016_j_ygyno_2021_02_017 crossref_primary_10_1016_j_cej_2024_150356 crossref_primary_10_1016_j_molliq_2023_121393 crossref_primary_10_1002_jso_26102 crossref_primary_10_1016_j_ijrobp_2020_06_012 crossref_primary_10_1007_s00432_023_05174_3 crossref_primary_10_1136_ijgc_2020_001446 crossref_primary_10_3390_cancers12030686 crossref_primary_10_3390_cancers15010271 crossref_primary_10_1016_j_canrad_2021_11_016 crossref_primary_10_1007_s00761_022_01293_7 crossref_primary_10_1007_s00129_025_05343_0 crossref_primary_10_1111_cas_15310 crossref_primary_10_1016_j_ygyno_2019_09_023 crossref_primary_10_1111_jog_14915 crossref_primary_10_2478_ahem_2025_0004 crossref_primary_10_1136_ijgc_2024_005522 crossref_primary_10_1080_07853890_2023_2177883 crossref_primary_10_3389_fonc_2025_1570732 crossref_primary_10_1080_21678707_2020_1784723 crossref_primary_10_1007_s00066_023_02061_1 crossref_primary_10_1007_s11864_025_01345_1 crossref_primary_10_1007_s00066_020_01632_w crossref_primary_10_1007_s10147_020_01744_4 crossref_primary_10_1016_j_ygyno_2020_05_018 crossref_primary_10_1136_bmjmed_2022_000152 crossref_primary_10_1016_j_ejogrb_2021_11_423 crossref_primary_10_1136_ijgc_2022_004073 crossref_primary_10_1016_j_ajog_2021_05_034 crossref_primary_10_1016_j_clon_2021_05_009 crossref_primary_10_1007_s12672_024_01403_4 crossref_primary_10_1016_j_bpobgyn_2021_06_002 crossref_primary_10_3390_cancers16112084 crossref_primary_10_1016_j_ygyno_2022_10_004 crossref_primary_10_1016_j_ijbiomac_2021_05_074 crossref_primary_10_1136_ijgc_2020_001797 crossref_primary_10_7759_cureus_24710 crossref_primary_10_1007_s11654_024_00628_7 crossref_primary_10_3390_cancers13225848 crossref_primary_10_1016_j_yao_2023_01_015 crossref_primary_10_1007_s40944_021_00566_0 crossref_primary_10_1371_journal_pmed_1003111 |
| Cites_doi | 10.1016/S0360-3016(02)02913-9 10.1016/j.ygyno.2015.01.546 10.1038/sj.bjc.6603279 10.1006/gyno.2001.6301 10.1006/gyno.1999.5569 10.1006/gyno.1996.0274 10.1016/j.ejca.2010.06.002 10.1200/JCO.2015.62.5459 10.1006/gyno.2002.6713 10.1016/j.ygyno.2008.11.014 10.1016/S0360-3016(02)02947-4 10.1006/gyno.2002.6789 10.1006/gyno.2001.6278 10.1200/JCO.2004.00.7617 10.1016/j.ygyno.2004.02.008 10.1097/GRF.0b013e3182185baa 10.1006/gyno.2001.6157 10.1016/S0140-6736(08)61767-5 10.1016/j.ygyno.2010.12.338 10.1186/1748-717X-9-141 10.1016/S1470-2045(18)30079-2 10.1016/S0140-6736(00)02139-5 10.1016/S0140-6736(09)62163-2 10.1016/j.ygyno.2006.08.027 10.1200/JCO.2004.02.088 10.1016/j.ygyno.2003.11.048 10.1016/j.ygyno.2012.03.034 10.1016/j.ygyno.2012.07.112 10.1016/j.ygyno.2008.10.006 10.1016/j.ygyno.2006.02.007 10.1016/j.ygyno.2007.09.029 10.1200/JCO.2004.07.184 10.1016/S0360-3016(01)01566-8 10.1016/S0360-3016(03)00531-5 10.1177/0163278705275340 10.1016/S0360-3016(01)01590-5 |
| ContentType | Journal Article |
| Copyright | Copyright © 2019 Massachusetts Medical Society. All rights reserved. Copyright © 2019 Massachusetts Medical Society. |
| Copyright_xml | – notice: Copyright © 2019 Massachusetts Medical Society. All rights reserved. – notice: Copyright © 2019 Massachusetts Medical Society. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7RV 7X7 7XB 8AO 8C1 8FE 8FH 8FI ABUWG AFKRA AN0 AZQEC BBNVY BEC BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ GUQSH HCIFZ K0Y LK8 M0R M0T M1P M2M M2O M2P M7P MBDVC NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS PSYQQ Q9U 7X8 5PM |
| DOI | 10.1056/NEJMoa1813181 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Nursing & Allied Health Database ProQuest Health & Medical Collection ProQuest Central (purchase pre-March 2016) ProQuest Pharma Collection Public Health Database ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection ProQuest Central (Alumni) ProQuest Central UK/Ireland British Nursing Database ProQuest Central Essentials ProQuest Biological Science Collection eLibrary (ProQuest) ProQuest Central (New) (NC LIVE) ProQuest Natural Science Collection ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student Research Library Prep ProQuest SciTech Premium Collection New England Journal of Medicine Biological Sciences Consumer Health Database Healthcare Administration Database PML(ProQuest Medical Library) Psychology Database Research Library Science Database ProQuest Biological Science Database (NC LIVE) Research Library (Corporate) Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China ProQuest One Psychology ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Psychology Research Library Prep ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials elibrary ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing New England Journal of Medicine ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences ProQuest Health & Medical Research Collection Health Research Premium Collection Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection ProQuest Research Library ProQuest Central (New) ProQuest Public Health ProQuest Biological Science Collection ProQuest Central Basic ProQuest Science Journals ProQuest Family Health ProQuest One Academic Eastern Edition British Nursing Index with Full Text ProQuest Health Management ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest Psychology Journals ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) MEDLINE - Academic |
| DatabaseTitleList | ProQuest One Psychology MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7RV name: Nursing & Allied Health Database url: https://search.proquest.com/nahs sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1533-4406 |
| EndPage | 2326 |
| ExternalDocumentID | PMC6948006 31189035 10_1056_NEJMoa1813181 NJ201906133802408 |
| Genre | Original Article Clinical Trial, Phase III Multicenter Study Randomized Controlled Trial Journal Article Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: NCI NIH HHS grantid: U10 CA180868 – fundername: NCI NIH HHS grantid: UG1 CA233191 – fundername: NCI NIH HHS grantid: U10 CA180822 – fundername: NCI NIH HHS grantid: UG1 CA189867 – fundername: NCI NIH HHS grantid: UG1 CA233331 – fundername: NCI NIH HHS grantid: U10 CA027469 – fundername: NCI NIH HHS grantid: CA 27469 – fundername: NCI NIH HHS grantid: UG1 CA233193 – fundername: NCI NIH HHS grantid: U10 CA037517 – fundername: NCI NIH HHS grantid: CA 37517 |
| GroupedDBID | - 0R 0WA 123 186 1VV 29N 2KS 2WC 34G 39C 4 4.4 53G 55 5RE 7FN 7RV 7X7 85S 8AO 8C1 8FE 8FH 8FI AACLI AAEJM AAIKC AALRV AAPBV AAQQT AARDX AAWTL ABACO ABEHJ ABFLS ABIVO ABOCM ABPPZ ABPTK ABQIJ ABUWG ABWJO ACGFS ACGOD ACJLH ACNCT ACPRK ACRZS ADBBV ADBIT ADCBC ADRHT AENEX AETEA AFFNX AFHKK AFKRA AGFXO AGNAY AHMBA AJJEV AJVPN ALMA_UNASSIGNED_HOLDINGS AN0 AQUVI AZQEC BBAFP BBNVY BCU BENPR BES BHPHI BKEYQ BKNYI BLC BNQBC BPHCQ BVXVI C45 CJ0 CO CS3 DCD DU5 DWQXO DZ EBS EJD ET EX3 F5P FD8 FM. FYUFA GJ GNUQQ GUQSH HCIFZ HZ I4R IH2 K-O KM KOO L7B LK8 M0R M0T M1P M2M M2O M2P M7P MVM N9A NAPCQ NEJ O9- OK1 OMK OVD P-O P-S P2P PADUT PCD PQEST PQQKQ PQUKI PRINS PROAC PSQYO QJJ RHI RWL RXW S10 S6N SJFOW SJN TAE TAF TEORI TN5 TUQ TWZ UCV UKR UMD VQA W2G WH7 WOQ WOW X X7M XJT XYN XZL YCJ YNT YRY YZZ ZA5 ZHY ZR0 --- -DZ -ET -~X .-4 .55 .CO .GJ 0R~ 36B AAMNW AAYXX ABBLC ABCQX ABDQB ABJNI ABUFD ACKOT ACPFK ADUKH AERZD AFFHD AGHSJ BYPQX CCPQU CITATION H13 HF~ HMCUK HZ~ N4W PHGZM PHGZT PJZUB PPXIY PQGLB PSYQQ UKHRP YFH YR2 YR5 YYP ZCA ZVN ~KM AFOSN ALIPV CGR CUY CVF ECM EIF NPM R.3 UIG VXZ YIF YIN Z5M 7XB BEC K0Y MBDVC PKEHL Q9U 7X8 PUEGO 5PM |
| ID | FETCH-LOGICAL-c445t-3108c155e6a32a129e924ab9e8cc861a09ac705058028a14f6a96dd630b2a81f3 |
| IEDL.DBID | DCD |
| ISICitedReferencesCount | 378 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000471299100010&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0028-4793 1533-4406 |
| IngestDate | Tue Nov 04 02:04:56 EST 2025 Wed Oct 01 14:33:32 EDT 2025 Sat Nov 29 14:20:55 EST 2025 Wed Feb 19 02:26:13 EST 2025 Sat Nov 29 03:02:03 EST 2025 Tue Nov 18 19:58:40 EST 2025 Tue Dec 21 14:38:52 EST 2021 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 24 |
| Language | English |
| License | http://www.nejmgroup.org/legal/terms-of-use.htm Copyright © 2019 Massachusetts Medical Society. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c445t-3108c155e6a32a129e924ab9e8cc861a09ac705058028a14f6a96dd630b2a81f3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3 Address reprint requests to Dr. Matei at the Division of Gynecologic Oncology, Northwestern University, 303 E. Superior St., Lurie 4-107, Chicago, IL 60610, or at daniela.matei@northwestern.edu. |
| ORCID | 0000-0002-8215-5887 |
| OpenAccessLink | https://www.nejm.org/doi/pdf/10.1056/NEJMoa1813181?articleTools=true |
| PMID | 31189035 |
| PQID | 2239268194 |
| PQPubID | 40644 |
| PageCount | 10 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_6948006 proquest_miscellaneous_2251104075 proquest_journals_2239268194 pubmed_primary_31189035 crossref_citationtrail_10_1056_NEJMoa1813181 crossref_primary_10_1056_NEJMoa1813181 mms_nejm_10_1056_NEJMoa1813181 |
| PublicationCentury | 2000 |
| PublicationDate | 20190613 2019-06-13 |
| PublicationDateYYYYMMDD | 2019-06-13 |
| PublicationDate_xml | – month: 06 year: 2019 text: 20190613 day: 13 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: Boston |
| PublicationTitle | The New England journal of medicine |
| PublicationTitleAlternate | N Engl J Med |
| PublicationYear | 2019 |
| Publisher | Massachusetts Medical Society |
| Publisher_xml | – name: Massachusetts Medical Society |
| References | Yost, KJ, Eton, DT (r014) 2005; 28 Miller, D, Filiaci, V, Fleming, G (r012) 2012; 125 Blake, P, Swart, AM, Orton, J (r016) 2009; 373 Havrilesky, LJ, Cragun, JM, Calingaert, B (r024) 2007; 104 Alektiar, KM, McKee, A, Lin, O (r028) 2002; 54 Meyer, LA, Bohlke, K, Powell, MA (r020) 2015; 33 Randall, ME, Filiaci, VL, Muss, H (r009) 2006; 24 McMeekin, DS, Lashbrook, D, Gold, M (r004) 2001; 82 Aalders, J, Abeler, V, Kolstad, P, Onsrud, M (r015) 1980; 56 Hogberg, T, Signorelli, M, de Oliveira, CF (r033) 2010; 46 Mariani, A, Webb, MJ, Keeney, GL, Aletti, G, Podratz, KC (r001) 2002; 86 Thigpen, JT, Brady, MF, Homesley, HD (r035) 2004; 22 Nout, RA, Smit, VT, Putter, H (r018) 2010; 375 Maggi, R, Lissoni, A, Spina, F (r031) 2006; 95 Schorge, JO, Molpus, KL, Goodman, A, Nikrui, N, Fuller, AF (r008) 1996; 63 Mundt, AJ, McBride, R, Rotmensch, J, Waggoner, SE, Yamada, SD, Connell, PP (r021) 2001; 50 Homesley, HD, Filiaci, V, Gibbons, SK (r011) 2009; 112 Keys, HMRJ, Roberts, JA, Brunetto, VL (r019) 2004; 92 Takeshima, N, Nishida, H, Tabata, T, Hirai, Y, Hasumi, K (r025) 2001; 82 Kiess, AP, Damast, S, Makker, V (r030) 2012; 127 de Boer, SM, Powell, ME, Mileshkin, L (r034) 2018; 19 Susumu, N, Sagae, S, Udagawa, Y (r032) 2008; 108 Mariani, A, Webb, MJ, Keeney, GL, Haddock, MG, Aletti, G, Podratz, KC (r002) 2002; 87 Geller, MA, Ivy, JJ, Ghebre, R (r036) 2011; 121 Fleming, GF, Brunetto, VL, Cella, D (r013) 2004; 22 Greven, K, Winter, K, Underhill, K, Fontenesci, J, Cooper, J, Burke, T (r010) 2006; 103 Stewart, KD, Martinez, AA, Weiner, S (r022) 2002; 54 Alektiar, KM, Makker, V, Abu-Rustum, NR (r027) 2009; 112 Nelson, G, Randall, M, Sutton, G, Moore, D, Hurteau, J, Look, K (r007) 1999; 75 Lewin, SN (r023) 2011; 54 Lu, SM, Chang-Halpenny, C, Hwang-Graziano, J (r037) 2015; 137 Bruzzone, M, Miglietta, L, Franzone, P, Gadducci, A, Boccardo, F (r005) 2004; 93 Foerster, R, Kluck, R, Rief, H, Rieken, S, Debus, J, Lindel, K (r029) 2014; 9 Creutzberg, CL, van Putten, WL, Koper, PC (r017) 2000; 355 Sood, BM, Jones, J, Gupta, S (r026) 2003; 57 Mundt, AJ, Murphy, KT, Rotmensch, J, Waggoner, SE, Yamada, SD, Connell, PP (r006) 2001; 50 McMeekin, DS, Lashbrook, D, Gold, M, Johnson, G, Walker, JL, Mannel, R (r003) 2001; 81 e_1_3_4_3_2 e_1_3_4_2_2 e_1_3_4_9_2 e_1_3_4_8_2 e_1_3_4_7_2 e_1_3_4_6_2 e_1_3_4_5_2 e_1_3_4_4_2 e_1_3_4_22_2 e_1_3_4_23_2 e_1_3_4_20_2 e_1_3_4_21_2 e_1_3_4_26_2 e_1_3_4_27_2 e_1_3_4_24_2 e_1_3_4_25_2 e_1_3_4_28_2 e_1_3_4_29_2 e_1_3_4_30_2 Aalders J (e_1_3_4_16_2) 1980; 56 e_1_3_4_11_2 e_1_3_4_34_2 e_1_3_4_12_2 e_1_3_4_33_2 e_1_3_4_32_2 e_1_3_4_10_2 e_1_3_4_31_2 e_1_3_4_15_2 e_1_3_4_38_2 e_1_3_4_37_2 e_1_3_4_13_2 e_1_3_4_36_2 e_1_3_4_14_2 e_1_3_4_35_2 e_1_3_4_19_2 e_1_3_4_17_2 e_1_3_4_18_2 33069345 - Int J Radiat Oncol Biol Phys. 2020 Nov 15;108(4):839-845 |
| References_xml | – volume: 50 start-page: 1154 year: 2001 end-page: 1160 ident: r006 article-title: Surgery and postoperative radiation therapy in FIGO Stage IIIC endometrial carcinoma. publication-title: Int J Radiat Oncol Biol Phys – volume: 108 start-page: 226 year: 2008 end-page: 233 ident: r032 article-title: Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study. publication-title: Gynecol Oncol – volume: 82 start-page: 470 year: 2001 end-page: 473 ident: r025 article-title: Positive peritoneal cytology in endometrial cancer: enhancement of other prognostic indicators. publication-title: Gynecol Oncol – volume: 87 start-page: 112 year: 2002 end-page: 117 ident: r002 article-title: Stage IIIC endometrioid corpus cancer includes distinct subgroups. publication-title: Gynecol Oncol – volume: 54 start-page: 79 year: 2002 end-page: 85 ident: r028 article-title: Is there a difference in outcome between stage I-II endometrial cancer of papillary serous/clear cell and endometrioid FIGO grade 3 cancer? publication-title: Int J Radiat Oncol Biol Phys – volume: 57 start-page: 208 year: 2003 end-page: 216 ident: r026 article-title: Patterns of failure after the multimodality treatment of uterine papillary serous carcinoma. publication-title: Int J Radiat Oncol Biol Phys – volume: 33 start-page: 2908 year: 2015 end-page: 2913 ident: r020 article-title: Postoperative radiation therapy for endometrial cancer: American Society of Clinical Oncology clinical practice guideline endorsement of the American Society for Radiation Oncology evidence-based guideline. publication-title: J Clin Oncol – volume: 9 start-page: 141 year: 2014 end-page: 141 ident: r029 article-title: Survival of women with clear cell and papillary serous endometrial cancer after adjuvant radiotherapy. publication-title: Radiat Oncol – volume: 86 start-page: 38 year: 2002 end-page: 44 ident: r001 article-title: Assessment of prognostic factors in stage IIIA endometrial cancer. publication-title: Gynecol Oncol – volume: 63 start-page: 34 year: 1996 end-page: 39 ident: r008 article-title: The effect of postsurgical therapy on stage III endometrial carcinoma. publication-title: Gynecol Oncol – volume: 46 start-page: 2422 year: 2010 end-page: 2431 ident: r033 article-title: Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer — results from two randomised studies. publication-title: Eur J Cancer – volume: 82 start-page: 375 year: 2001 end-page: 379 ident: r004 article-title: Nodal distribution and its significance in FIGO stage IIIc endometrial cancer. publication-title: Gynecol Oncol – volume: 50 start-page: 1145 year: 2001 end-page: 1153 ident: r021 article-title: Significant pelvic recurrence in high-risk pathologic stage I–IV endometrial carcinoma patients after adjuvant chemotherapy alone: implications for adjuvant radiation therapy. publication-title: Int J Radiat Oncol Biol Phys – volume: 137 start-page: 28 year: 2015 end-page: 33 ident: r037 article-title: Sequential versus “sandwich” sequencing of adjuvant chemoradiation for the treatment of stage III uterine endometrioid adenocarcinoma. publication-title: Gynecol Oncol – volume: 127 start-page: 321 year: 2012 end-page: 325 ident: r030 article-title: Five-year outcomes of adjuvant carboplatin/paclitaxel chemotherapy and intravaginal radiation for stage I-II papillary serous endometrial cancer. publication-title: Gynecol Oncol – volume: 22 start-page: 2159 year: 2004 end-page: 2166 ident: r013 article-title: Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group study. publication-title: J Clin Oncol – volume: 95 start-page: 266 year: 2006 end-page: 271 ident: r031 article-title: Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial. publication-title: Br J Cancer – volume: 81 start-page: 273 year: 2001 end-page: 278 ident: r003 article-title: Analysis of FIGO stage IIIc endometrial cancer patients. publication-title: Gynecol Oncol – volume: 103 start-page: 155 year: 2006 end-page: 159 ident: r010 article-title: Final analysis of RTOG 9708: adjuvant postoperative irradiation combined with cisplatin/paclitaxel chemotherapy following surgery for patients with high-risk endometrial cancer. publication-title: Gynecol Oncol – volume: 373 start-page: 137 year: 2009 end-page: 146 ident: r016 article-title: Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis. publication-title: Lancet – volume: 22 start-page: 3902 year: 2004 end-page: 3908 ident: r035 article-title: Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a Gynecologic Oncology Group study. publication-title: J Clin Oncol – volume: 104 start-page: 401 year: 2007 end-page: 405 ident: r024 article-title: The prognostic significance of positive peritoneal cytology and adnexal/serosal metastasis in stage IIIA endometrial cancer. publication-title: Gynecol Oncol – volume: 112 start-page: 142 year: 2009 end-page: 145 ident: r027 article-title: Concurrent carboplatin/paclitaxel and intravaginal radiation in surgical stage I-II serous endometrial cancer. publication-title: Gynecol Oncol – volume: 93 start-page: 345 year: 2004 end-page: 352 ident: r005 article-title: Combined treatment with chemotherapy and radiotherapy in high-risk FIGO stage III-IV endometrial cancer patients. publication-title: Gynecol Oncol – volume: 24 start-page: 36 year: 2006 end-page: 44 ident: r009 article-title: Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group study. publication-title: J Clin Oncol – volume: 375 start-page: 816 year: 2010 end-page: 823 ident: r018 article-title: Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. publication-title: Lancet – volume: 56 start-page: 419 year: 1980 end-page: 427 ident: r015 article-title: Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma: clinical and histopathologic study of 540 patients. publication-title: Obstet Gynecol – volume: 19 start-page: 295 year: 2018 end-page: 309 ident: r034 article-title: Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. publication-title: Lancet Oncol – volume: 75 start-page: 211 year: 1999 end-page: 214 ident: r007 article-title: FIGO stage IIIC endometrial carcinoma with metastases confined to pelvic lymph nodes: analysis of treatment outcomes, prognostic variables, and failure patterns following adjuvant radiation therapy. publication-title: Gynecol Oncol – volume: 355 start-page: 1404 year: 2000 end-page: 1411 ident: r017 article-title: Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. publication-title: Lancet – volume: 121 start-page: 112 year: 2011 end-page: 117 ident: r036 article-title: A phase II trial of carboplatin and docetaxel followed by radiotherapy given in a “Sandwich” method for stage III, IV, and recurrent endometrial cancer. publication-title: Gynecol Oncol – volume: 125 start-page: 771 year: 2012 end-page: 771 ident: r012 article-title: Randomized phase III noninferiority trial of first-line chemotherapy for metastatic or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. publication-title: Gynecol Oncol – volume: 92 start-page: 744 year: 2004 end-page: 751 ident: r019 article-title: A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. publication-title: Gynecol Oncol – volume: 112 start-page: 543 year: 2009 end-page: 552 ident: r011 article-title: A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: a Gynecologic Oncology Group study. publication-title: Gynecol Oncol – volume: 28 start-page: 172 year: 2005 end-page: 191 ident: r014 article-title: Combining distribution- and anchor-based approaches to determine minimally important differences: the FACIT experience. publication-title: Eval Health Prof – volume: 54 start-page: 527 year: 2002 end-page: 535 ident: r022 article-title: Ten-year outcome including patterns of failure and toxicity for adjuvant whole abdominopelvic irradiation in high-risk and poor histologic feature patients with endometrial carcinoma. publication-title: Int J Radiat Oncol Biol Phys – volume: 54 start-page: 215 year: 2011 end-page: 218 ident: r023 article-title: Revised FIGO staging system for endometrial cancer. publication-title: Clin Obstet Gynecol – ident: e_1_3_4_29_2 doi: 10.1016/S0360-3016(02)02913-9 – ident: e_1_3_4_38_2 doi: 10.1016/j.ygyno.2015.01.546 – ident: e_1_3_4_32_2 doi: 10.1038/sj.bjc.6603279 – ident: e_1_3_4_26_2 doi: 10.1006/gyno.2001.6301 – ident: e_1_3_4_8_2 doi: 10.1006/gyno.1999.5569 – ident: e_1_3_4_9_2 doi: 10.1006/gyno.1996.0274 – volume: 56 start-page: 419 year: 1980 ident: e_1_3_4_16_2 article-title: Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma: clinical and histopathologic study of 540 patients. publication-title: Obstet Gynecol – ident: e_1_3_4_34_2 doi: 10.1016/j.ejca.2010.06.002 – ident: e_1_3_4_21_2 doi: 10.1200/JCO.2015.62.5459 – ident: e_1_3_4_2_2 doi: 10.1006/gyno.2002.6713 – ident: e_1_3_4_12_2 doi: 10.1016/j.ygyno.2008.11.014 – ident: e_1_3_4_23_2 doi: 10.1016/S0360-3016(02)02947-4 – ident: e_1_3_4_3_2 doi: 10.1006/gyno.2002.6789 – ident: e_1_3_4_5_2 doi: 10.1006/gyno.2001.6278 – ident: e_1_3_4_10_2 doi: 10.1200/JCO.2004.00.7617 – ident: e_1_3_4_6_2 doi: 10.1016/j.ygyno.2004.02.008 – ident: e_1_3_4_24_2 doi: 10.1097/GRF.0b013e3182185baa – ident: e_1_3_4_4_2 doi: 10.1006/gyno.2001.6157 – ident: e_1_3_4_17_2 doi: 10.1016/S0140-6736(08)61767-5 – ident: e_1_3_4_37_2 doi: 10.1016/j.ygyno.2010.12.338 – ident: e_1_3_4_30_2 doi: 10.1186/1748-717X-9-141 – ident: e_1_3_4_35_2 doi: 10.1016/S1470-2045(18)30079-2 – ident: e_1_3_4_18_2 doi: 10.1016/S0140-6736(00)02139-5 – ident: e_1_3_4_19_2 doi: 10.1016/S0140-6736(09)62163-2 – ident: e_1_3_4_25_2 doi: 10.1016/j.ygyno.2006.08.027 – ident: e_1_3_4_36_2 doi: 10.1200/JCO.2004.02.088 – ident: e_1_3_4_20_2 doi: 10.1016/j.ygyno.2003.11.048 – ident: e_1_3_4_13_2 doi: 10.1016/j.ygyno.2012.03.034 – ident: e_1_3_4_31_2 doi: 10.1016/j.ygyno.2012.07.112 – ident: e_1_3_4_28_2 doi: 10.1016/j.ygyno.2008.10.006 – ident: e_1_3_4_11_2 doi: 10.1016/j.ygyno.2006.02.007 – ident: e_1_3_4_33_2 doi: 10.1016/j.ygyno.2007.09.029 – ident: e_1_3_4_14_2 doi: 10.1200/JCO.2004.07.184 – ident: e_1_3_4_22_2 doi: 10.1016/S0360-3016(01)01566-8 – ident: e_1_3_4_27_2 doi: 10.1016/S0360-3016(03)00531-5 – ident: e_1_3_4_15_2 doi: 10.1177/0163278705275340 – ident: e_1_3_4_7_2 doi: 10.1016/S0360-3016(01)01590-5 – reference: 33069345 - Int J Radiat Oncol Biol Phys. 2020 Nov 15;108(4):839-845 |
| SSID | ssj0000149 |
| Score | 2.6934779 |
| Snippet | After a median of nearly 4 years of follow-up, the use of radiotherapy combined with chemotherapy in patients with stage III or IVA endometrial carcinoma was... Stage III or IVA endometrial cancer carries a significant risk of systemic and locoregional recurrence. In this randomized phase 3 trial, we tested whether 6... BackgroundStage III or IVA endometrial cancer carries a significant risk of systemic and locoregional recurrence.MethodsIn this randomized phase 3 trial, we... Stage III or IVA endometrial cancer carries a significant risk of systemic and locoregional recurrence.BACKGROUNDStage III or IVA endometrial cancer carries a... |
| SourceID | pubmedcentral proquest pubmed crossref mms |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 2317 |
| SubjectTerms | Abdomen Adjuvants Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols - therapeutic use Cancer therapies Carcinoma Chemoradiotherapy Chemoradiotherapy, Adjuvant Chemotherapy Chemotherapy, Adjuvant Computer centers Disease-Free Survival Endometrial cancer Endometrial Neoplasms - mortality Endometrial Neoplasms - pathology Endometrial Neoplasms - surgery Endometrial Neoplasms - therapy Endometrium Female Humans Kaplan-Meier Estimate Metastasis Middle Aged Neoplasm Recurrence, Local Neoplasm Staging Neoplasm, Residual Oncology Patients Platinum Prognosis Quality of Life Radiation therapy Recurrence Statistics, Nonparametric Survival Treatment Outcome Uterine cancer Vagina |
| SummonAdditionalLinks | – databaseName: Nursing & Allied Health Database dbid: 7RV link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3JTsMwEB2xCXFhX8omIyFORGRxnfiEqgrEARBCgLhFjuOIojYpTYvUv2cmdQtFwIVrPAfHM5553t4DOPaS0KTClU7iyszhEVeOQpTvZL5JI-lrIf20EpsIb2-j52d5ZzfcSnutcpwTq0SdFpr2yM-wjElfYP3i5903h1Sj6HTVSmjMwrxHtRvjObx_-kIfZeGv3UGyHJtY889Iab5QWN4wpr2pmjTb6ZQ_wc3vtya_lKHLlf_-wCosWwDKGqOIWYMZk6_D4o09Yt-A60b6OkB43WfEJWDfZw1Ztz0o2T0RGZAnGUJddk1lsD1kDXuNgF3kadExlQ4Ia9Kn3iY8Xl48NK8cK7ngaM7rfczIbqQRYhihAl8hFjC4PlOJNJHWkfCUK5UOSfwuwjFVHs-EkiJNReAmvoq8LNiCubzIzQ6wRGSu9oyu3kvVuZacwEyI-CbRvvLDGpyOBz3Wlo-cZDHacXUuXhfxlI9qcDIx746IOH4zPEQPxrl57fxmsD92UGwnbBl_eqcGR5NmnGp0fqJyUwzIBtEpJr2wXoPtUSxMuhLgQk26AbaEU1EyMSAa7-mWvPVS0XkLyRG1i92_u7UHS4jViDHC8YJ9mOv3BuYAFvR7v1X2Dqu4_wBsjwiO priority: 102 providerName: ProQuest |
| Title | Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer |
| URI | https://nejm.org/doi/full/10.1056/NEJMoa1813181 https://www.ncbi.nlm.nih.gov/pubmed/31189035 https://www.proquest.com/docview/2239268194 https://www.proquest.com/docview/2251104075 https://pubmed.ncbi.nlm.nih.gov/PMC6948006 |
| Volume | 380 |
| WOSCitedRecordID | wos000471299100010&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVBGY databaseName: New England Journal of Medicine (UW System Shared) customDbUrl: eissn: 1533-4406 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: DCD dateStart: 19900101 isFulltext: true titleUrlDefault: https://www.nejm.org/medical-index providerName: Massachusetts Medical Society – providerCode: PRVPQU databaseName: Biological Science Database customDbUrl: eissn: 1533-4406 dateEnd: 20250906 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: M7P dateStart: 19800103 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Consumer Health Database customDbUrl: eissn: 1533-4406 dateEnd: 20250906 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: M0R dateStart: 19800103 isFulltext: true titleUrlDefault: https://search.proquest.com/familyhealth providerName: ProQuest – providerCode: PRVPQU databaseName: Healthcare Administration Database customDbUrl: eissn: 1533-4406 dateEnd: 20250906 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: M0T dateStart: 19800103 isFulltext: true titleUrlDefault: https://search.proquest.com/healthmanagement providerName: ProQuest – providerCode: PRVPQU databaseName: Nursing & Allied Health Database customDbUrl: eissn: 1533-4406 dateEnd: 20250906 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: 7RV dateStart: 19800103 isFulltext: true titleUrlDefault: https://search.proquest.com/nahs providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1533-4406 dateEnd: 20250906 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: BENPR dateStart: 19800103 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Health & Medical Collection customDbUrl: eissn: 1533-4406 dateEnd: 20250906 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: 7X7 dateStart: 19800103 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: Psychology Database customDbUrl: eissn: 1533-4406 dateEnd: 20250906 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: M2M dateStart: 19800103 isFulltext: true titleUrlDefault: https://www.proquest.com/psychology providerName: ProQuest – providerCode: PRVPQU databaseName: Public Health Database customDbUrl: eissn: 1533-4406 dateEnd: 20250906 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: 8C1 dateStart: 19800103 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest – providerCode: PRVPQU databaseName: Research Library (subscription) customDbUrl: eissn: 1533-4406 dateEnd: 20250906 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: M2O dateStart: 19800103 isFulltext: true titleUrlDefault: https://search.proquest.com/pqrl providerName: ProQuest – providerCode: PRVPQU databaseName: Science Database (subscription) customDbUrl: eissn: 1533-4406 dateEnd: 20250906 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: M2P dateStart: 19800103 isFulltext: true titleUrlDefault: https://search.proquest.com/sciencejournals providerName: ProQuest |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1LaxsxEB7yKKWXpO-6TY0Kpacu2dWu9Ti6jkMPsWtMWnxbtFotSbDXwY9A_n1nZNnEeVB6-Q6rWRAaSfPp9Q3A16SQrhSxjopYV1GmMhMZZPlRxV2pNLdC89Inm5D9vhqN9GAHjtdvYWp3NfEH-DSiaQd6nR3-mHLDTw0GJOyFuNzZx76mKVfDSefkjl5U4LthyyiIaj74fSsI7U4m88f45f1rknfizunhf9f4JRwEisnaqz7xCnZc_Rqe98Ih-hs4a5dXSyTQC0ZqAeEF1i27Hi_nbEhSBeQrhmSWnVGgG9-ydrgowLp1OZ04n-mDdejT7C38Pu2ed35GIalCZLOstcA5N1YWSYQTJuUGo73DFZgptFPWKpGYWBsrKb2dwkY0SVYJo0VZijQuuFFJlb6DvXpauw_AClHFNnHWv4hqZVZnRFckMpjCcsNlA76vWzm3QXGcEl-Mc3_y3RL5Vgs14NvG_HoltfGUYRNdllPDP2VwtPZmHobkPEcepLlAApQ14MumGAcTnZCY2k2XZIP8E6c12WrA-5XzN1VJcSmm4xRL5Fa32BiQUPd2SX154QW7hc6Ql4uP_6r3J3iBfIxUIaIkPYK9xWzpPsMze7O4nM-asCuHfwhH0qNCVJ2kCfs_uv3BsOmHAmIvHno8J-Q9j788Dgjl4C9xwQKg |
| linkProvider | Massachusetts Medical Society |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3fb9MwED5tAwEv_P5RGMNIwBPREse14weEqrFp07oKoSH1LTiOIza1SWlaUP8p_kbuUqesiPG2B17jU5TE5_u-i8_fAbyKMuVyGeogC3URiESYwCDLDwru8kRzKzXPm2YTajBIhkP9cQN-tmdhqKyyjYlNoM4rS__IdxHGNJeIX-L95FtAXaNod7VtobF0i2O3-IEpW_3u6APO72vOD_ZP9w4D31UgsEJ0Zxh0wsQiijppYm4Q7hymICbTLrE2kZEJtbGK-rslCL0mEoU0Wua5jMOMmyQqYrzvJlzDOK6ohEwN1QW5Kk-3_R8rr-mJHGOXOttXBuEU11C0hoGb43H9N3r7Z5XmBdg7uPO_fbC7cNsTbNZbroh7sOHK-3DjxJcQPIB-Lz-fY_owY6SV4M-fLdhkNK_ZJxJqIE9lSOVZn2B-tGA9XybB9su8Grumzwnbo0vTh_D5St7lEWyVVemeAMtkEdrI2eY8WFdYLYisKeRvmeWGqw68bSc5tV5vndp-jNJm378r0zWf6MCblflkKTRymeEOekxauvPxZQbbrUOkPiDV6W9v6MDL1TCGEtofMqWr5mSD7BuDuup24PHS91aPEmMiqsMYR9SaV64MSKZ8faQ8-9rIlUstMCuRT__9WC_g5uHpST_tHw2On8Et5KWkjhFE8TZszaZz9xyu2--zs3q606w5Bl-u2md_AbkcYx8 |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Nb9NAEB21BVVc-C4ESlkk4IQVe71eew8IRW0jqqZRhYrUm1mv16JVYoc4AeWv8euYcdahQZRbD1yzo8iJ3857Y8--AXgdZLHNpa-8zFeFJxKhPY0q3yu4zRPFjVQ8b4ZNxMNhcn6uTjfgZ3sWhtoq25zYJOq8MvSMvIs0prhE_hLdwrVFnB70P0y-eTRBit60tuM0lhA5tosfWL7V748O8F6_4bx_eLb_0XMTBjwjRDTDBOQnBhnVSh1yjdRnsRzRmbKJMYkMtK-0iWnWW4I0rANRSK1knsvQz7hOgiLE792EW7GIOLWTnfhnV6yrnPR2T6-cvyfqjS5Nua80Uivup2CNDzfH4_pvUvfPjs0rFNi_9z__effhrhPerLfcKQ9gw5YPYfvEtRY8gkEvv5xjWTFj5KHgzqUt2GQ0r9knMnAgBDOU-GxA9D9asJ5rn2CHZV6NbTP_hO3TR9PH8PlGfssObJVVaZ8Cy2Thm8Ca5pxYJIwSJOJi1HWZ4ZrHHXjX3vDUOB92GgcySpt-gEima_jowNtV-GRpQHJd4B6iJy3t5fi6gN0WHKlLVHX6GxkdeLVaxhRD7410aas5xaAqx2QfRx14ssTh6lJCLFCVH-JKvIbQVQDZl6-vlBdfGxtzqQRWK_LZvy_rJWwjVNPB0fD4OdxBuUqmGV4Q7sLWbDq3L-C2-T67qKd7zfZj8OWmIfsLA8dr7w |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Adjuvant+Chemotherapy+plus+Radiation+for+Locally+Advanced+Endometrial+Cancer&rft.jtitle=The+New+England+journal+of+medicine&rft.au=Matei%2C+Daniela&rft.au=Filiaci%2C+Virginia&rft.au=Randall%2C+Marcus+E.&rft.au=Mutch%2C+David&rft.date=2019-06-13&rft.issn=0028-4793&rft.eissn=1533-4406&rft.volume=380&rft.issue=24&rft.spage=2317&rft.epage=2326&rft_id=info:doi/10.1056%2FNEJMoa1813181&rft.externalDBID=n%2Fa&rft.externalDocID=10_1056_NEJMoa1813181 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0028-4793&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0028-4793&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0028-4793&client=summon |